Heart drug safety trial in kids: small but important step
NCT ID NCT06149104
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the safety of the drug sacubitril/valsartan in Japanese children with heart failure. Eight children who had already been in a previous trial took the drug to see if any side effects occurred. The goal was to gather more safety information and provide the drug until a child-friendly version becomes available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacubitril/valsartan
What this could lead to
If successful, this could confirm that sacubitril/valsartan is safe for Japanese children with heart failure, supporting its use as a treatment option.
What could go wrong
This is a very small study (8 participants) focused only on safety, not effectiveness. It may not detect rare side effects or apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ōbu, Aichi-ken, 474 8710, Japan
-
Novartis Investigative Site
Ōmura, Nagasaki, 856-8562, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113 8655, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 157-8535, Japan
-
Novartis Investigative Site
Saitama, 330 8777, Japan
-
Novartis Investigative Site
Toyama, 930-0194, Japan